Summary
64 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 52% a year over the last 3 years.
- It holds more cash than debt: $70.5M against $2.86M.
- The share price is below the Bulios Fair Price.
- Out of every 100 CAD of revenue, 16 CAD is left as free cash.
What to watch
- It missed profit estimates 7 times in the last 8 quarters.
- It earns only 5.0 CAD a year on every 100 CAD of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 62.3 CAD for 1 CAD of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (CAD)
Diluted EPS (CAD)
- Analyst estimate
Revenue grew by 51% a year over 5 years. Over the last 3 years it grew by 40% a year. For the next fiscal year analysts expect revenue to grow by 22%. Earnings per share grew by 52% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 CAD of revenue goes
- Cost of sales 25 CAD
- Research and development 28 CAD
- Sales and administration 32 CAD
- Taxes and other 9.0 CAD
- Net profit 5.9 CAD
Net profit, industry median (Medical - Healthcare Information Services) 4.7 CAD
Out of every 100 CAD of revenue, 5.9 CAD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 1
- Hold 0
- Sell 0
No analyst has published a price target.
100% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.